Daily Aspirin Shows Promise in Cancer Prevention for High-Risk Individuals

A clinical trial is testing whether daily aspirin can protect against cancer development in people with Lynch syndrome, a genetic condition that significantly increases the risk of developing bowel cancer. Recent trials and studies have strengthened evidence that aspirin might reduce the chances of colorectal cancer occurring or spreading.

Approximately 80% of people with Lynch syndrome develop bowel cancer during their lifetime.

The Trial and Its Participants

The trial is led by John Burn, a professor of clinical genetics at Newcastle University. One participant, Nick James, was the first person to enroll. He underwent genetic testing after family members developed cancer and was found to carry the gene for Lynch syndrome.

Notably, James has taken aspirin for 10 years as part of the trial without developing cancer.

Background and Medical Guidance

Aspirin is a pain medication with a long history, having been used for approximately 4,000 years. Based on emerging evidence, some countries have updated medical guidelines to include aspirin as a first-line protection for high-risk individuals.

Experts emphasize that any decision to take aspirin for this purpose should only be done under medical supervision. Research is ongoing to understand the precise biological reasons why aspirin might have this protective effect.